SalioGen Therapeutics Funding & Investors
Cambridge, MA
SalioGen Therapeutics advances in curative genetic therapies using its Exact DNA Integration Technology (EDIT) platform, a mammal-derived genome engineering technology. It is focused on providing durable, safe, and affordable non-viral gene therapies to more patients with inherited diseases. Looking ahead, SalioGen will also explore the EDIT platform’s capabilities to streamline cell therapy, cell engineering, and biologics manufacturing to help an even broader population of patients in need.
saliogen.comTotal Amount Raised: $135,000,000
SalioGen Therapeutics Funding Rounds
Series B
$115,000,000
Series B Investors
EPIQ Capital GroupGordonMD Global InvestmentsT. Rowe PriceCystic Fibrosis FoundationRD FundFidelity InvestmentsD1 Capital PartnersSymBiosisSeries A
$20,000,000
Series A Investors
PBM Capital Group
Funding info provided by Diffbot.